Linus Alexander Völker

I usually think twice before posting preprints. But this time it’s different. MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research. 🧵

Refractory #iTTP in the #caplacizumab era is exceedingly rare and oftentimes related to secondary factors: Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura ashpublications.org/blood/article-…

Large multicenter retrospective analysis indicating that the incorporation of caplacizumab into treatment of immune TTP in the ICU improves the ICU survival. Overall ICU survival was high. doi.org/10.1002/ajh.70… @Ralph_Wendt @LinusAlexanderV @oncologne @UKKoeln

Obtaining a thorough family history is so important in kidney disease....but often more difficult than expected in clinical practice... 10 tips on how to take a proper family history in CKD patient care url: academic.oup.com/ckj/article/do…

1/ 🚨 Big news from our Genes&Kidney Working Group at the @ERAkidney We just released a consensus statement in Nephrology Dialysis Transplantation aiming to bring us closer to precision medicine in CKD. 🧬🩺 🧵 THREAD 👇

@Basalus Great overview! But don’t forget thrombotic thrombocytopenic purpura, particularly in young females! #TTP

1/13 #Stroke in young patients (<50) is rare but rising. Unlike older adults, strokes here often stem from uncommon causes—not atherosclerosis. Here’s a breakdown clinicians must know. #NeuroTwitter #MedTwitter ⚠️🧠

🚨 The Capla1000+ project published! Early use of caplacizumab significantly reduces mortality and time to response. 💥 3-mo survival: 98.5% vs. 94% (controls) 🩸 Bleeding in 2.4%, mostly elderly 💡 Age key mortality factor 🔗tinyurl.com/fpx8uuvp #TTP #Caplacizumab

@alex_epi_tria @WilliamAird4 They certainly are encouraging. There might also be a role for advanced anti-CD20-therapies but clearly there is not enough data on refractory TTP.

1/6 TPE-FREE MANAGEMENT OF IMMUNE TTP (iTTP) Retrospective study from Austria and Germany ADAMTS13 activity at baseline <10% in all patients Treatment group (TPE-free): 42 acute iTTP episodes in 41 patients received TPE-free management with caplacizumab + steroids +/- Ritux

Free scientific illustrations for biologists! 😍 @NIH has released a library of 500+ free scientific illustrations to create figures, presentations, and illustrations! all freely available in the public domain. Retweet and spread the message! bioart.niaid.nih.gov

Made it to the LBCT session And it is a hyponatremia trial! #KidneyWk

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange. This is a real change in treatment of our iTTP patients! Congratulations to the authors for this nice paper ashpublications.org/blood/article/…

iTTP treatment w/o plasma exchange -final print version now out! Exploring novel treatment paradigms and alleviating treatment burden with the support of great international colleagues! doi.org/10.1182/blood.…

What’s new in nephrotic syndrome? An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes ⁦- thanks to all coauthors and great collab w/@Ralph_Wendt⁩ mdpi.com/2227-9059/12/1…

Wie übernehmen wir Patienten unter laufender CPR im Schockraum? Wie lagern wir um, wechseln das Device, kommunizieren etc? Solche (+ viele andere) Situationen üben wir in unseren interdisziplinären SR-Trainings im Schwerpunkt KAN der Uniklinik Köln #ukk

🧵Thread on frontline caplacizumab and plasma exchange in TTP🚨 With advancing care for immune thrombotic thrombocytopenic purpura (iTTP), let’s discuss frontline caplacizumab (capla) and the future for therapeutic plasma exchange (TPE) ⤵️ #hemetwitter #TTP #caplacizumab 1/22

@SR_DeshpandeMD @HTRSFellows @HTRStoday @isth @AaronGoodman33 @survivingTTP Thank you for engaging with our work! Nice thread! Some points are certainly up to discussion (cost effectiveness, mortality, risk stratification). At this point I still also have to strongly advise against the indiscriminate use of TPE-free treatment. We hopefully get there!

Our comment on Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura | New England Journal of Medicine nejm.org/doi/full/10.10… @Ralph_Wendt and Paul Brinkkötter

Food is medicine...and what we eat governs outcome in many types of diseases (if not all). This includes solid organ transplantation. Fueling the success of transplantation through nutrition:... : Current Opinion in Organ Transplantation journals.lww.com/co-transplanta…